Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Lees

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Blood|May 3, 2002
The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethalityPatricia A Taylor, Christopher J Lees, Bruce R Blazar
Blood|February 28, 2002
Allogenic fetal liver cells have a distinct competitive engraftment advantage over adult bone marrow cells when infused into fetal as compared with adult severe combined immunodeficient recipientsPatricia A Taylor, Ronald T McElmurry, Christopher J Lees, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 23, 2003
B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]Patricia A Taylor, Christopher J Lees, Sylvie Fournier, et al.
Blood|October 18, 2002
Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditionsPatricia A Taylor, Christopher J Lees, Jessica M Wilson, et al.
International Journal of Molecular Sciences|May 14, 2022
Engineering CRISPR/Cas9 for Multiplexed Recombinant Coagulation Factor ProductionColby J Feser, Christopher J Lees, Daniel T Lammers, et al.
Blood|July 4, 2007
Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD)Patricia A Taylor, Michael J Ehrhardt, Christopher J Lees, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 18, 2010
Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type IMark J Osborn, Ron T McElmurry, Christopher J Lees, et al.
Bioengineering (Basel, Switzerland)|March 6, 2021
CRISPR/Cas9-Based Lateral Flow and Fluorescence DiagnosticsMark J Osborn, Akshay Bhardwaj, Samuel P Bingea, et al.
Blood|July 11, 2008
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejectionPatricia A Taylor, Michael J Ehrhardt, Christopher J Lees, et al.
International Journal of Molecular Sciences|March 23, 2018
CRISPR/Cas9-Based Cellular Engineering for Targeted Gene OverexpressionMark J Osborn, Christopher J Lees, Amber N McElroy, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Blood|May 3, 2002
The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethalityPatricia A Taylor, Christopher J Lees, Bruce R Blazar
Blood|February 28, 2002
Allogenic fetal liver cells have a distinct competitive engraftment advantage over adult bone marrow cells when infused into fetal as compared with adult severe combined immunodeficient recipientsPatricia A Taylor, Ronald T McElmurry, Christopher J Lees, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 23, 2003
B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]Patricia A Taylor, Christopher J Lees, Sylvie Fournier, et al.
Blood|October 18, 2002
Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditionsPatricia A Taylor, Christopher J Lees, Jessica M Wilson, et al.
International Journal of Molecular Sciences|May 14, 2022
Engineering CRISPR/Cas9 for Multiplexed Recombinant Coagulation Factor ProductionColby J Feser, Christopher J Lees, Daniel T Lammers, et al.
Blood|July 4, 2007
Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD)Patricia A Taylor, Michael J Ehrhardt, Christopher J Lees, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 18, 2010
Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type IMark J Osborn, Ron T McElmurry, Christopher J Lees, et al.
Bioengineering (Basel, Switzerland)|March 6, 2021
CRISPR/Cas9-Based Lateral Flow and Fluorescence DiagnosticsMark J Osborn, Akshay Bhardwaj, Samuel P Bingea, et al.
Blood|July 11, 2008
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejectionPatricia A Taylor, Michael J Ehrhardt, Christopher J Lees, et al.
International Journal of Molecular Sciences|March 23, 2018
CRISPR/Cas9-Based Cellular Engineering for Targeted Gene OverexpressionMark J Osborn, Christopher J Lees, Amber N McElroy, et al.
Pageof 2